Interleukin-31 monoclonal antibody
US10421807B2 · kind B2 · utility
75Cited by
6References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 5, 2018 |
| Grant date | Sep 24, 2019 |
| Priority date | — |
| Expiry date | Dec 5, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/54
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A cell-based assay for assessing the functional activity of a canine or feline IL-31 inhibitor candidate is provided. Such a canine or feline IL-31 inhibitor candidate can be an isolated antibody that specifically binds to at least one of canine Interleukin-31 (IL-31) or feline IL-31. Such antibodies can be in the form of diagnostic and/or veterinary compositions useful for treating a pruritic and/or allergic condition in dogs or cats.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.